

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/034960 A1

(51) International Patent Classification⁷: **A61K 31/66**,
C07D 311/38, C07C 15/18, 39/15, A61K 31/05, 31/04,
A61P 39/06, C12Q 1/68, A61K 31/015, 31/352, 31/353,
31/397, 31/122, 31/404, 31/40, 31/44, 31/505, 35/00

(74) Agent: **HORNE, Doak, D.**; c/o Gowling Lafleur Hender-
son LLP, Suite 1400, 700 - 2nd Street S.W., Calgary, Al-
berta T2P 4V5 (CA).

(21) International Application Number:
PCT/CA2004/001818

(22) International Filing Date: 8 October 2004 (08.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(30) Priority Data:
60/510,669 10 October 2003 (10.10.2003) US
60/510,342 10 October 2003 (10.10.2003) US
10/762,796 22 January 2004 (22.01.2004) US
10/807,800 24 March 2004 (24.03.2004) US

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
RESVERLOGIX CORP. [CA/CA]; 202, 279 Mid-
park Way S.E., Calgary, Alberta T2X 1M2 (CA).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WONG, Norman**
[CA/CA]; 616 Edgemont Bay N.W., Calgary, Alberta T3A
2K8 (CA). **TUCKER, Joe** [CA/CA]; 1016 23rd Avenue
N.W., Calgary, Alberta T2M 1T6 (CA). **MCCAFFREY,
David, Robert** [CA/CA]; 1632 Evergreen Hill S.W., Cal-
gary, Alberta T2Y 3A9 (CA).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT

(57) Abstract: Compounds and methods are provided for treating patients suffering from health condition associated with an ex-
pression state of a gene such as fertility disorders, cancer, proliferative diseases, vascular diseases, wounds requiring therapeutic
intervention, inflammation, and pulmonary disorders by administering to said patient a compound capable of modulating egr-1
and/or an egr-1 response element consensus sequence thereby altering the expression state of said gene. Also described are new
methods for screening compounds to identify effectors of egr-1 and/or egr-1 consensus sequence elements and methods for treating
patients by administering such effectors to modulate egr-1 and/or egr-1 consensus sequences to thereby modify expression of genes
associated therewith to in turn treat diseases or other physiological conditions associated with such gene expression.

WO 2005/034960 A1